CANNABIS therapeutics company Creso Pharma (ASX: CPH) has signed a distribution deal with Doetsch Grether to market its hemp-based cannaQIX®10 product throughout Switzerland and Lichtenstein.

Under the terms of the 10-year deal, Doetsch Grether will market and distribute the cannaQIX®10 nutraceutical food supplement to drug store chains in accordance with Swiss federal food laws.

As Doetsch Grether is a leader in the European pharmaceuticals market, the agreement means Creso Pharma’s product will have access to more than 2,300 outlets across the two countries.

Dr Miri Halperin Wernli, CEO and co-founder of Creso Pharma, says the company is looking forward to breaking into the Swiss market with its flagship product that is designed to provide stress and anxiety relief to consumers.

“We are proud for having achieved a further milestone obtaining the marketing approval for cannaQIX®10 in Switzerland,” she says. Read more